D Wade Clapp

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2138526/publications.pdf

Version: 2024-02-01

51 papers	2,452 citations	430874 18 h-index	233421 45 g-index
54 all docs	54 docs citations	54 times ranked	4304 citing authors

#	Article	IF	Citations
1	Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nature Genetics, 1996, 12, 144-148.	21.4	555
2	Selumetinib in Children with Inoperable Plexiform Neurofibromas. New England Journal of Medicine, 2020, 382, 1430-1442.	27.0	360
3	Fanconi anaemia and cancer: an intricate relationship. Nature Reviews Cancer, 2018, 18, 168-185.	28.4	275
4	Fanconi Anemia Proteins Function in Mitophagy and Immunity. Cell, 2016, 165, 867-881.	28.9	205
5	Loss of FancC Function Results in Decreased Hematopoietic Stem Cell Repopulating Ability. Blood, 1999, 94, 1-8.	1.4	185
6	Social learning and amygdala disruptions in Nf1 mice are rescued by blocking p21-activated kinase. Nature Neuroscience, 2014, 17, 1583-1590.	14.8	106
7	Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis. Journal of Clinical Investigation, 2018, 128, 2848-2861.	8.2	101
8	Developmental Regulation of the Immune System. Seminars in Perinatology, 2006, 30, 69-72.	2.5	88
9	A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation. Human Molecular Genetics, 2015, 24, 1-8.	2.9	76
10	The importance of nerve microenvironment for schwannoma development. Acta Neuropathologica, 2016, 132, 289-307.	7.7	62
11	Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation. Human Molecular Genetics, 2019, 28, 2752-2762.	2.9	54
12	The Highest Concentration of Primitive Hematopoietic Progenitor Cells in Cord Blood Is Found in Extremely Premature Infants. Pediatric Research, 1996, 39, 820-825.	2.3	49
13	Cabozantinib for neurofibromatosis type 1â€“related plexiform neurofibromas: a phase 2 trial. Nature Medicine, 2021, 27, 165-173.	30.7	46
14	Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formation. Oncotarget, 2016, 7, 7403-7414.	1.8	30
15	Fanconi anemia and the cell cycle: new perspectives on aneuploidy. F1000prime Reports, 2014, 6, 23.	5.9	23
16	A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. Cancer Research, 2017, 77, 5706-5711.	0.9	22
17	Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors. Gene Therapy, 2019, 26, 277-286.	4.5	21
18	Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas. Pediatric Blood and Cancer, 2016, 63, 206-213.	1.5	20

#	Article	IF	Citations
19	Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. PLoS ONE, 2021, 16, e0252048.	2.5	19
20	Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. PLoS ONE, 2018, 13, e0197350.	2.5	17
21	Schwannoma development is mediated by Hippo pathway dysregulation and modified by RAS/MAPK signaling. JCI Insight, 2020, 5, .	5.0	14
22	Nf1^{+/â˜’}monocytes/macrophages induce neointima formation via CCR2 activation. Human Molecular Genetics, 2016, 25, 1129-1139.	2.9	13
23	A molecular basis for neurofibroma-associated skeletal manifestations in NF1. Genetics in Medicine, 2020, 22, 1786-1793.	2.4	12
24	Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. British Journal of Cancer, 2021, 124, 1566-1580.	6.4	12
25	PAK1 inhibition reduces tumor size and extends the lifespan of mice in a genetically engineered mouse model of Neurofibromatosis Type 2 (NF2). Human Molecular Genetics, 2021, 30, 1607-1617.	2.9	12
26	Genetic disruption of the small GTPase RAC1 prevents plexiform neurofibroma formation in mice with neurofibromatosis type 17. Journal of Biological Chemistry, 2020, 295, 9948-9958.	3.4	7
27	Addressing Gaps in Pediatric Scientist Development: The Department Chair View of 2 AMSPDC-Sponsored Programs. Journal of Pediatrics, 2020, 222, 7-12.e4.	1.8	6
28	Chemopreventative celecoxib fails to prevent schwannoma formation or sensorineural hearing loss in genetically engineered murine model of neurofibromatosis type 2. Oncotarget, 2018, 9, 718-725.	1.8	6
29	A proteasome-resistant fragment of NIK mediates oncogenic NF-Î¹B signaling in schwannomas. Human Molecular Genetics, 2019, 28, 572-583.	2.9	5
30	Irradiation of Nf1 mutant mouse models of spinal plexiform neurofibromas drives pathologic progression and decreases survival. Neuro-Oncology Advances, 2021, 3, vdab063.	0.7	4
31	Mitotic Errors Promote Genomic Instability and Leukemia in a Novel Mouse Model of Fanconi Anemia. Frontiers in Oncology, 2021, 11, 752933.	2.8	4
32	Hospitalist Medicineâ€"Chairs' Perspective of Specialty Status and Training Requirements. Journal of Pediatrics, 2018, 193, 4-8.e1.	1.8	3
33	Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK. Molecular Cancer Therapeutics, 2020, 19, 2382-2395.	4.1	3
34	Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1. Pediatric Blood and Cancer, 2020, 67, e28372.	1.5	3
35	Murine and Human NF1 Haploinsufficient Mast Cells Promote Alterations in Fibroblast Function and Organization of the Extracellular Matrix in Three-Dimensional Collagen Lattices and this Gain in Function Is Abrogated by the Addition of STI-571.. Blood, 2004, 104, 1465-1465.	1.4	3
36	From bedside to bench and back: Translating ASD models. Progress in Brain Research, 2018, 241, 113-158.	1.4	2

#	Article	IF	Citations
37	SIK2 kinase synthetic lethality is driven by spindle assembly defects in FANCAâ€deficient cells. Molecular Oncology, 2022, 16, 860-884.	4.6	2
38	Suprasynergistic Peripheral Blood Stem Cell Mobilization in Normal and Fanconi Anemia Knockout Mice by the Combination of G-CSF Plus the CXCR4 Antagonist AMD3100 and the CXCR2 Agonist GRO Î². Blood, 2006, 108, 3185-3185.	1.4	2
39	A Modified Foamy Viral Envelope Enhances Gene Transfer Efficiency and Reduces Toxicity of Lentiviral FANCA Vectors in Fanca-/- HSCs.. Blood, 2009, 114, 696-696.	1.4	2
40	Generation Of FANCA-/- Human CD34+ Hematopoietic Stem Cells By shRNA Knockdown. Blood, 2013, 122, 2903-2903.	1.4	2
41	Foamy Viral Vectors Efficiently Transduce Quiescent Hematopoietic Stem/Progenitor Cells (HSC) and Restore the Long Term Repopulating Activity of Fancc â^'/â^' Stem Cells.. Blood, 2005, 106, 182-182.	1.4	1
42	Loss of Pak1 Corrects Multiple Gain of Function Phenotypes in Nf1+/â^' Mast Cells.. Blood, 2007, 110, 236-236.	1.4	1
43	PAK1 Regulates Eotaxin-Mediated Murine Eosinophil Migration in Vitro and In Vivo. Blood, 2011, 118, 18-18.	1.4	1
44	NFM-09. PRELIMINARY REPORT OF A MULTICENTER, PHASE 2 STUDY OF BEVACIZUMAB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS 2 AND PROGRESSIVE VESTIBULAR SCHWANNOMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY. Neuro-Oncology, 2018, 20, i144-i144.	1.2	0
45	Functional Analysis of Leukemia-Associated PTPN11 Mutations in Primary Hematopoietic Cells.. Blood, 2004, 104, 2423-2423.	1.4	0
46	Comparative Functional Genomic Analysis of Myelodysplasia (MDS) in Fanconi Anemia (FA).. Blood, 2006, 108, 2636-2636.	1.4	0
47	Kinase Suppressor of Ras Plays a Critical Role in Modulating Inflammatory Mast Cell Functions.. Blood, 2007, 110, 2407-2407.	1.4	0
48	Mast Cells and Tumor Progression.. Blood, 2009, 114, SCI-33-SCI-33.	1.4	0
49	Ezrin Regulates Hematopoietic Stem/Progenitor Cell Motility. Blood, 2011, 118, 1282-1282.	1.4	0
50	Normal Hematopoiesis and Neurofibromin-Deficient Myeloproliferative Disease Require Erk. Blood, 2012, 120, 704-704.	1.4	0
51	FANCA Controls Mitotic Phosphosignaling Networks To Ensure Genome Stability During Cell Division. Blood, 2013, 122, 801-801.	1.4	0